Introduction
Severe aortic regurgitation (AR) is a well-known complication following left ventricular assist device (LVAD) implantation. 1, 2 In these patients, severe AR leads to recirculation of regurgitant blood generating low antegrade left ventricular output which may result in impaired hemodynamics. Treatment of these patients by secondary open heart surgery is considered a high-risk procedure.
We herein describe a case of severe AR in a native aortic valve following LVAD implantation treated by transfemoral transcatheter aortic valve implantation (TAVI) using the latest generation self-expandable Boston Scientific Acurate neo transcatheter heart valve (THV).
Case Report
A 61-year-old female patient (168 cm, 54 kg, BMI 19.1 kg/m 2 ) was admitted 8 months following LVAD implantation (Medtronic, Ventricular Assist System HVAD, Miami Lakes, Florida, United States) in new-onset acute heart failure (New York Heart Association [NYHA] III-IV). Comorbidities included chronic renal failure (creatinine 2.5 mg/dL), recurrent hem-orrhagic gastritis, multiple sclerosis, and condition after malignant melanoma resulting in an Society of Thoracic Surgery-Predicted Risk of Mortality (STS PROM) score of 8.74% and logistic EuroSCORE I of 16.5%. Transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) revealed new-onset severe AR with volume overload left ventricular dilatation. Morphologically, the aortic valve was tricuspid and free of any calcification (►Fig. 1A,B). AR was eccentric caused by retraction of the noncoronary cusp. Due to her poor general status (cardiac cachexia, use of wheeled walker) and thus increased perioperative risk for open redo surgery, the local interdisciplinary heart team indicated off-label TAVI.
TAVI procedure was performed according to local standard protocol. Preprocedural echocardiogram-gated multislice computed-tomography (MSCT) demonstrated an effective perimeter-derived annulus diameter of 22.4 mm, annulus perimeter of 70.5 mm, and area of 390.3 mm 2 (►Fig. 1). Coronary distances from the aortic plane were 14.9 mm (right) and 11.4 mm (left), sinus diameters were 26.2 mm/27.9 mm/ 27.8 mm for non-/left-/right-coronary sinuses (►Fig. 1). Subsequently, an Acurate neo, size M THV (Boston Scientific) was chosen to provide sufficient oversizing. The intervention was Keywords ► left ventricular assist device ► aortic regurgitation ► transcatheter aortic valve implantation ► heart failure Abstract Background In patients treated by left ventricular assist device (LVAD), aortic regurgitation (AR) may occur. Secondary surgery to correct AR is considered high risk.
Case Description We report a case of severe AR following LVAD implantation in a patient who was subsequently treated by transcatheter aortic valve implantation (TAVI) using the latest generation self-expandable transcatheter heart valve (THV) (Boston Scientific Acurate neo, size M [Boston Scientific, Marlborough, Massachusetts, United States]). TAVI followed modified procedural protocol and sizing algorithm. THV implantation without prior balloon aortic valvuloplasty resulted in an adequate valve function without leakage. Conclusion This THV may be particularly well suited for TAVI subsequent to LVAD implantation if modified sizing and deployment considerations are appreciated.
then conducted via right-sided percutaneous transfemoral access using standard preclosure (ProGlide, Abbott Vascular, Santa Clara, California, United States). In view of the risk of entrapment of a straight guidewire in the LVAD inflow, a wire enforced pigtail catheter was used for retrograde valve passage. After crossing, invasive assessment of baseline hemodynamics was performed (heart rate [ was inserted and placed carefully in a para-apical position immediately adjacent to the LVAD inflow cannula. By the guidance of TEE and fluoroscopy and using a single diagnostic noncoronary cusp pigtail catheter, the THV was inserted via an 18Fr Boston iSleeve sheath and advanced to an intra-annular position with the annular marker band slightly above the native aortic valve annulus (►Fig. 2). Immediately prior to the initiation of deployment, LVAD output was reduced from 4.6 L/min, 2,600 RPM, 4.0 Watt to 2.3 L/min, 1,800 RPM, 1.6 to 1.8 Watt to achieve a stable intra-annular THV position. After the development of the aortic stabilization arches and the upper stent crown, correct implant height was angiographically confirmed. The second step of deployment was performed in a brief phase of rapid ventricular pacing. Particular care was taken during delivery system retrieval with centering of the nose cone by retraction of the Safari guidewire. After delivery system retrieval previously reduced LVAD output parameters were changed back to the original LVAD adjustment. A ventricular pigtail catheter was inserted for invasive assessment of hemodynamics. An improvement of CO was observed (HR 85 , complete absence of paravalvular leakage (PVL), and a transprosthetic gradient of peak/mean 4/1 mm Hg. Throughout the procedure, completely stable hemodynamics were noted with low doses of catecholamines.
Following the procedure, the patient was transferred to the intensive care unit for 24 hours. During the further postprocedural course, the patient recovered rapidly with early mobilization. TTE prior to discharge documented an excellent THV position without any PVL.
Regarding Valve Academic Research Consortium (VARC-2) adjudicated clinical end points one complication was observed: the patient was readmitted 2 weeks after THV implantation for the known recurrent hemorrhagic gastritis. At latest follow-up, 100 days after the procedure, TTE showed an adequate THV function without any leakage.
Discussion
Secondary occurrence of relevant AR after LVAD implantation is a well-known complication. 1,2 A progress in AR severity often increases symptoms of heart failure and is related to poor prognosis. 3 These conditions represent a serious medical challenge and require an exceptional therapeutic concept. A primary surgical regime in these patients characterized with end stage heart failure, previous cardiac surgery, and frequently high comorbidity burden should be considered critically. In these cases, TAVI is an alternative less invasive option. However, in this alternative setting some challenges have to be considered. THV has been developed for the treatment of aortic stenosis. As a consequence, anchoring of THV in patients with pure AR in a native aortic valve without annular or leaflet calcifications represents an off-label indication and requires a modified sizing and implant algorithm.
To date, anecdotal reports of treatment with THV in patients with pure AR following LVAD implantation exist. 4 In most of these cases, CoreValve THVs were used (Medtronic, Inc, Minneapolis, Minnesota, United States) and TAVI was demonstrated to be a reasonable option. However, from larger series on use of this particular self-expandable THV in pure, noncalcified AR it is known that the implant procedure is not trivial with relevant rates of sequential valve implantation for malpositioning of the first THV as well as an incidence of residual AR! grade II in 21% of the patients. 5,6 This is the first report of the latest generation self-expandable Acurate neo THV for the pure noncalcified AR in the presence of an LVAD. This case demonstrates technical feasibility and safety and adds to the existing literature on this type of THV for the treatment of AR (15). In contrast to the CoreValve THV, the x-shaped design of this THV stent allows for sufficient anchoring even in the absence of calcification by aligning the stent waist with the aortic annulus. However, in contrast to use in aortic stenosis, a modified sizing algorithm has to be appreciated with a more pronounced oversizing to prevent THV migration. From experience with this type of THV in AR patients in general, the maximum effective annulus diameter should not exceed 24.5 mm and eccentricity of the annulus should also be carefully assessed before indicating such a procedure (own unpublished data). An aortic annulus above 24.5 mm most likely does not offer the possibility of adequate oversizing in AR with this particular THV with consecutive risk of device migration. Due to the low number of cases performed at our or other centers, these sizing recommendation have to rely on clinical experience rather than complete datasets. Also, since the use of this type of THV for AR remains off-label use at present, no general conclusions should be drawn from the few anecdotal reports or small series published to date. In other reports of valve size selection a tendency to over-size 9 AE 4% was chosen compared with nominal diameters of 23, 25, and 27 mm for the sizes S, M, and L of this particular THV. 7 Furthermore, a slightly higher initial THV position seems advisable due to the lower extent of counterforce in a noncalcified landing zone. To perform the second deployment step in a brief phase of rapid ventricular pacing also seems prudent to stabilize the aortic root and to promote a controlled THV release from the delivery catheter. Finally, reduction of LVAD flow to a minimum immediately prior to THV deployment can be advised to reduce suction toward the left ventricular outflow tract.
Conclusion
In selected cases, TAVI using this latest generation selfexpandable THV system for correction of severe AR following LVAD implantation is technically feasible and represents an alternative less invasive treatment option. Careful MSCT assessment of annular dimensions as well as modified sizing and implantation strategies is the key to success.
